Abstract We report on a case of a mobile left atrial thrombus formation on an atrial septal defect occluder system (28 mm StarFLEX â -Occluder) despite 6 months of postprocedural anticoagulation with phenprocoumon and platelet antiaggregation with aspirin in a 69-year-old woman. The closure was performed because of a significant left to right atrial shunt (Qp/Qs 1.8) with enlargement of the right atrial and ventricular cavities and impairment of right ventricular function in the presence of persistent atrial fibrillation and chronic heart failure (NYHA IIeIII). The 6-month follow up by transoesophageal echocardiography (TEE) revealed the floating thrombus located at the left atrial side of the occluder.
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Abstract We report on a case of a mobile left atrial thrombus formation on an atrial septal defect occluder system (28 mm StarFLEX â -Occluder) despite 6 months of postprocedural anticoagulation with phenprocoumon and platelet antiaggregation with aspirin in a 69-year-old woman. The closure was performed because of a significant left to right atrial shunt (Qp/Qs 1.8) with enlargement of the right atrial and ventricular cavities and impairment of right ventricular function in the presence of persistent atrial fibrillation and chronic heart failure (NYHA IIeIII). We are presenting this case in context with a review of the current literature focussing on predictors of thrombus formation on transcatheter ASD-closure devices.
Case presentation
A 69-year-old woman was admitted for transcatheter closure of an atrial septal defect (ASD).
The patient showed symptoms of chronic heart failure (NYHA IIeIII) and had a medical history of systemic hypertension for 19 years and received oral anticoagulation with phenprocoumon due to atrial fibrillation for 1 year. There were no episodes of systemic embolism or deep vein thrombosis in the past.
Echocardiography and cardiac catheterisation revealed an ASD leading to a significant left to right atrial shunt (Qp/Qs 1.8) with enlargement of the right atrial and ventricular cavities and impairment of right ventricular function. The patient underwent a TEE-guided transcatheter closure of the atrial septal defect under local anaesthesia using a 28 mm StarFLEX â -Occluder without residual shunt. The medication with phenprocuomon had been stopped 5 days prior to closure device implantation and changed to anticoagulation with intravenous heparin before and in the first days after ASD closure. Phenprocoumon was started again with a target INR of 2.5 and aspirin 100 mg per day was added.
The patient came back for a scheduled followup after 6 months. She did not report any complications during the period after closure device implantation to follow-up except episodes of epistaxis. Therefore aspirin 100 mg per day had been stopped by her general physician after 5 months. There was a reduction of heart failure symptoms (NYHA IeII). According to the weekly blood samples, the anticoagulation with phenprocoumon was strictly managed during the 6 months with INR values ranging between 2.0 and 3.0. TEE after 6 months showed a floating echogenic structure connected to the left atrial part of the well positioned StarFLEX â -Occluder without any additional atrial or ventricular thrombi and absence of spontaneous echo contrast (Fig. 1 ). There was no residual shunt on colour Doppler imaging. The patient was checked for a possible coagulation disorder although congenital or acquired hypercoagulation seemed rather improbable. The check up was performed without testing resistance to activated Protein C and Protein S deficiency because of ongoing therapy with phenprocoumon, and with heparin under continuing atrial fibrillation.
The patient was referred for surgery and underwent a successful explantation of the device together with the thrombotic apposition and a closure of the atrial septal defect using a pericardial patch (Fig. 2) .
Comment on the current literature
Transcatheter closure of different congenital atrial septal defects leading to paradoxical embolism or intracardiac shunt has become an effective and less invasive alternative to surgery. Appropriate anticoagulation after transcatheter device placement is discussed controversially especially in cases without history of systemic embolism. Patients without thromboembolism or neurologic events typically receive antiplatelet therapy for several months until the endothelialisation of the blood exposed parts has been completed. For patients with a history of stroke or atrial fibrillation, there are no established guidelines for postprocedural anticoagulation. Most of the patients receive warfarin, antiplatelet therapy, or different combinations.
In our department, patients undergoing a transcatheter device placement with a StarFLEX â -Occluder due to an ASD with significant shunt as well as paradoxical embolism in cases of PFO receive anticoagulation with phenprocoumon (target INR 2.5) together with antiplatelet therapy with aspirin 100 mg per day for 6 months in order to avoid postprocedural device associated thrombus formation.
Device associated atrial thrombi after transcatheter ASD-or PFO-closure are reported complications (Table 1) , but the true incidence may be underestimated and there are no randomised trials assessing independent predictors of device associated thrombi. There are no investigations comparing patients receiving a transcatheter closure with similar pre-and postprocedural risk factors for thromboembolism or different closure devices under the same anticoagulation regimen.
In a study, La Rosée et al. 6 analysed 102 consecutive patients treated for an ASD or PFO with the Amplatzer Thrombus formation on an atrial septal defect closure device 100 mg/day for 12 months together with clopidogrel 75 mg for 3 months. The majority of thrombi resolved after 6 months of anticoagulation and there was only one detectable thrombus after 1 year. There were no independent predictors of thrombus in this trial. Krumsdorf et al. 7 reported 1000 consecutive patients, 593 of them with PFO and 407 with an ASD. There were 20 device associated thrombi during the 4-week (n ¼ 14) or 6-month (n ¼ 6) follow up by TEE. Nine different closure devices were used. The thrombi occurred more often in patients with the CardioSEAL â (7.1%) or the StarFLEX â (5.7%) device compared to the Amplatzer â device (p < 0.05). There was a trend toward device associated thrombi in patients with persisting or new onset atrial fibrillation after the procedure (n ¼ 4; 6.2 vs. 20%; p < 0.05) as well as in patients with persisting atrial septal aneurysm (ASA) despite effective transcatheter closure (n ¼ 4; 1.3 vs. 20%, p < 0.01). It should be mentioned that the patients underwent platelet antiaggregation with aspirin and clopidogrel and most of the thrombi (17/20) disappeared after anticoagulation with either heparin or warfarin alone or under their combined therapy. Three of the thrombi had to be surgically explanted together with the device after persistence under anticoagulation.
A similar trend towards the type of closure device used as a possible independent predictor of thrombus formation was revealed by Anzai et al. 8 in a study with 66 consecutive patients treated for PFO or ASD with the Amplatzer â or CardioSEAL â closure system. Five thrombi were found on CardioSEAL â devices (p ¼ 0.02), none on the other system. Only one device was surgically removed, the other thrombi resolved under anticoagulation. ASA or atrial fibrillation were not identified as independent predictors of thrombus formation in this study.
In summary, there are only two studies trying to discriminate predictors of device associated thrombus formation after transcatheter closure. The trend towards persisting ASA as well as atrial fibrillation as possible independent risk factors or a preference for the CardioSEAL â or the later developed StarFLEX â occluder system in comparison with the Amlatzer device should be discussed very carefully; there are no randomised trials offering a randomly assigned patient collective with similar risk factors under the same or different anticoagulation regimens.
Cetta et al. 9 focused on a patient after transcatheter closure of a PFO with the CardioSEAL â closure device. A large left atrial thrombus formation occurred despite accurate warfarin therapy in the absence of arrhythmias or coagulation disorders.
In comparison, our case demonstrates an unexpected thrombus occurrence despite effective combined anticoagulation and platelet antiaggregation.
The optimal anticoagulation for transcatheter closure of atrial septal defects at increased thrombotic risk is not known. In the presence of atrial fibrillation and/or enlarged cavities, routine TEE follow-up of the patients is suggested. TEE follow up should be performed after 6 months in cases without additional prothrombotic risk factors. An early TEE follow up after 4 weeks could be useful in the presence of increased thrombotic risk.
